1. Home
  2. VIR vs ARR Comparison

VIR vs ARR Comparison

Compare VIR & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • ARR
  • Stock Information
  • Founded
  • VIR 2016
  • ARR 2008
  • Country
  • VIR United States
  • ARR United States
  • Employees
  • VIR N/A
  • ARR N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • ARR Real Estate Investment Trusts
  • Sector
  • VIR Health Care
  • ARR Real Estate
  • Exchange
  • VIR Nasdaq
  • ARR Nasdaq
  • Market Cap
  • VIR 1.0B
  • ARR 1.1B
  • IPO Year
  • VIR 2019
  • ARR N/A
  • Fundamental
  • Price
  • VIR $7.47
  • ARR $18.68
  • Analyst Decision
  • VIR Buy
  • ARR Hold
  • Analyst Count
  • VIR 5
  • ARR 2
  • Target Price
  • VIR $36.40
  • ARR $21.00
  • AVG Volume (30 Days)
  • VIR 1.4M
  • ARR 1.8M
  • Earning Date
  • VIR 02-20-2025
  • ARR 02-12-2025
  • Dividend Yield
  • VIR N/A
  • ARR 15.40%
  • EPS Growth
  • VIR N/A
  • ARR N/A
  • EPS
  • VIR N/A
  • ARR 2.41
  • Revenue
  • VIR $78,618,000.00
  • ARR $185,086,000.00
  • Revenue This Year
  • VIR N/A
  • ARR N/A
  • Revenue Next Year
  • VIR N/A
  • ARR $295.11
  • P/E Ratio
  • VIR N/A
  • ARR $7.76
  • Revenue Growth
  • VIR N/A
  • ARR N/A
  • 52 Week Low
  • VIR $6.56
  • ARR $17.35
  • 52 Week High
  • VIR $13.09
  • ARR $21.93
  • Technical
  • Relative Strength Index (RSI)
  • VIR 45.87
  • ARR 42.53
  • Support Level
  • VIR $7.15
  • ARR $18.37
  • Resistance Level
  • VIR $7.56
  • ARR $19.22
  • Average True Range (ATR)
  • VIR 0.40
  • ARR 0.35
  • MACD
  • VIR -0.02
  • ARR -0.04
  • Stochastic Oscillator
  • VIR 24.79
  • ARR 24.41

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About ARR ARMOUR Residential REIT Inc.

ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.

Share on Social Networks: